TG Therapeutics (TGTX) shares are in focus after the company secured a new five year US$750 million senior secured credit ...

TG Therapeutics, Inc. (“TG” or “the Company”), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 ...

The company posted earnings per share (EPS) of $0.17, which fell short of the forecasted $0.19, marking a 10.53% negative surprise. Despite the EPS miss, TG Therapeutics exceeded revenue expectations, ...

TG Therapeutics Inc (NASDAQ: TGTX). shares have reached a new 52-week high, touching $43.03 amid a surge in investor confidence. According to InvestingPro data, the company boasts an impressive gross ...

The company had a nugget of good news in its third-quarter report. TG Therapeutics focuses on therapies to treat B-cell diseases. The company released its third-quarter earnings before the market ...

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701 ...

The company reported Q3 results that were much better than expected. An up-front licensing payment from Neuraxpharm was a big factor in these surprisingly good results. However, TG's U.S. sales of ...